Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood tests could reveal secrets of rectal cancer

NCT ID NCT02874885

Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

This study looks at tiny pieces of cancer cells or DNA floating in the blood of people with rectal cancer. Researchers want to see if these markers can help predict how the tumor responds to standard treatment. About 341 participants, including healthy volunteers, will provide blood samples over time. The goal is to better understand rectal cancer, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

341 people

The number who actually took part.

Started

Sep 2013

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy participants and patients diagnosed with rectal (or rectosigmoid) adenocarcinoma at MD Anderson Cancer Center.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * HEALTHY SUBJECT: No known diagnosis of colorectal cancer (CRC) or any other type of cancer for the last 10 years.(basal cell skin cancer is allowed). Subjects will be asked about their cancer history and a verbal confirmation is required * Any patient with diagnosis of rectal (or rectosigmoid) adenocarcinoma, including: * Patients with primary disease with or without neoadjuvant therapy; OR * Patients with recurrent disease with or without neoadjuvant therapy; OR * Patients with metastatic disease with or without prior treatment * No known current diagnosis of other invasive cancer; if prior diagnosis of other cancer, he/she has been free from cancer for \>= 3 years and is on no active treatment * Adequate mental and language capacity to provide consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced rectal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm rectosigmoid carcinoma rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced rectal adenocarcinoma Metastatic rectal adenocarcinoma Rectosigmoid adenocarcinoma Recurrent rectal adenocarcinoma Recurrent rectosigmoid carcinoma Stage III rectal cancer ajcc V8 Stage IIIA rectal cancer ajcc V8 Stage IIIB rectal cancer ajcc V8 Stage IIIC rectal cancer ajcc V8 Stage IV rectal cancer ajcc V8 Stage IVA rectal cancer ajcc V8 Stage IVB rectal cancer ajcc V8 Stage IVC rectal cancer ajcc V8

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.